会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 7. 发明授权
    • Optically active substituted phenylalkylamine derivatives
    • 光学活性取代苯基烷基胺衍生物
    • US5990151A
    • 1999-11-23
    • US981539
    • 1998-05-15
    • Atsuro NakazatoToshihito KumagaiTomoki MiyazawaKoumei OhtaYutaka KawashimaKatsuo Hatayama, deceased
    • Atsuro NakazatoToshihito KumagaiTomoki MiyazawaKoumei OhtaYutaka KawashimaKatsuo Hatayama, deceased
    • C07C217/60C07C217/62C07C271/16C07D333/16A61K31/135A61K31/38C07D333/06
    • C07C271/16C07C217/60C07C217/62C07D333/16
    • The present invention relates to an optically active, substituted phenylalkylamine derivative represented by Formula [1]: ##STR1## wherein A is a substituted or non-substituted phenyl or thienyl; X.sup.1 is hydrogen, halogen, hydroxyl or a substituted or non-substituted C.sub.1-5 alkoxy; R.sup.1 and R.sup.2 are equally or differently hydrogen, C.sub.1-7 alkyl, C.sub.3-7 alkenyl or C.sub.3-7 alkynyl; R.sup.3 is C.sub.1-10 alkyl, C.sub.2-10 alkenyl or C.sub.2-10 alkynyl; n is an integer from 2 to 5; and m is an integer from 1 to 4,or a pharmaceutically acceptable salt thereof, and pharmaceutical use of such compound or salt. The compound of the invention is excellent in sigma 1 receptor antagonism and useful for treating schizophrenia, depression, anxiety, cerebrovascular diseases/senile troublesome behaviors, and cognitive dysfunctions and motor dysfunctions such as Alzheimer's disease, Parkinson's disease and Huntington's disease which are neurodegenerative diseases. Further, the compound of the invention is also useful for treating dependence resulted from drug abuse.
    • PCT No.PCT / JP96 / 01613 Sec。 371日期:1998年5月15日 102(e)日期1998年5月15日PCT提交1996年6月13日PCT公布。 出版物WO97 / 00238 日本1997年1月3日本发明涉及由式[1]表示的光学活性的取代的苯基烷基胺衍生物:其中A是取代或未取代的苯基或噻吩基; X 1为氢,卤素,羟基或取代或未取代的C 1-5烷氧基; R1和R2同等或不同,氢,C1-7烷基,C3-7烯基或C3-7炔基; R3是C1-10烷基,C2-10烯基或C2-10炔基; n是2至5的整数; m为1〜4的整数,或其药学上可接受的盐,以及该化合物或其盐的药物用途。 本发明化合物在σ1受体拮抗作用方面优异,可用于治疗精神分裂症,抑郁症,焦虑症,脑血管疾病/老年麻醉行为,以及认知功能障碍和运动功能障碍如阿尔茨海默氏病,帕金森病和亨廷顿舞蹈病,这些疾病均为神经变性疾病。 此外,本发明的化合物还可用于治疗药物滥用引起的依赖性。